ILC has a relatively poor pre-operative tumor response rate following anti-estrogen therapy compared to other luminal IDCs, suggesting that estrogen receptor (ER) activity may be a less prominent driver of tumor growth in ILC than IDC [6]. This evidence concerns the gene ESR1 and neoplasm.